Here’s a groundbreaking development that could change the lives of millions: Aukera Therapeutics, a biotech spin-off from the University of Basel, has emerged from stealth mode, ready to tackle some of the most challenging neurological disorders. But here’s where it gets controversial—their approach involves targeting RAPTOR, a protein linked to mTOR, which has long been a focus of research but remains a complex and debated area in medical science. Could this be the breakthrough we’ve been waiting for?
On December 11, 2025, Aukera Therapeutics officially announced its entry into preclinical efficacy studies, backed by CHF 4.5 million in funding. Leading the charge is CEO and Co-founder Stefan Imseng, Ph.D., who is joined by new board member and investor David Urech, a seasoned biotech leader known for his role in Numab Therapeutics. With additional support from investors like Kickfund and Zürcher Kantonalbank, Aukera is poised to make waves in the biotech industry.
What sets Aukera apart? The company has harnessed AI-powered technology to screen billions of compounds, identifying a highly selective RAPTOR inhibitor. This inhibitor modulates the mTORC1 signaling network, offering a novel approach to treating neurological conditions associated with RAPTOR activity. But this is the part most people miss—RAPTOR’s role in mTORC1 dysregulation is still not fully understood, making Aukera’s work both pioneering and potentially transformative.
Stefan Imseng has a bold vision: to develop a therapy for Tuberous Sclerosis Complex (TSC), a rare genetic disorder that often begins in infancy and causes seizures, cognitive impairments, and other neuropsychiatric symptoms. “TSC is devastating for patients and their families,” Stefan explains. “By dampening mTORC1 activity with our RAPTOR inhibitors, we aim to reduce seizure frequency and severity, offering much-needed relief.”
But here’s the kicker—Aukera isn’t stopping at TSC. The company plans to expand its research to other mTORC1-related conditions, including neurodegeneration, metabolic disorders, and age-related diseases. This ambitious scope raises a thought-provoking question: Can a single target like RAPTOR truly address such a wide range of disorders? David Urech seems to think so. “The potential to impact over a million TSC patients, combined with Aukera’s scientific expertise, convinced me to invest and join the board,” he said.
Founded on groundbreaking research from Professors Michael N. Hall and Timm Maier at the University of Basel, Aukera combines mTOR expertise with cutting-edge AI-driven drug discovery. Their lead program focuses on rare neurological disorders, but the implications could extend far beyond. With funding from Venture Kick, BaseLaunch, and Innosuisse, Aukera is well-positioned to lead the charge in this emerging field.
So, what do you think? Is Aukera’s approach the future of neurological therapy, or is it too early to tell? Share your thoughts in the comments—let’s spark a conversation about the potential and challenges of targeting RAPTOR and mTORC1. For more information, reach out to Aukera’s team at [email protected] or +41 61 207 6081. The future of biotech is here—are you ready to be part of it?
